Gevokizumab (Xoma 052) is a humanized anti-IL-1β monoclonal antibody and isadministered intravenously or subcutaneously.[70,71,72] It has been studied in uveitis associated with BDand noninfectious scleritis.[62][63,64][73] Although rapidcontrol of BD-related uveitis was noted in the pilot and phase-2 studies,[70,71] the phase-3 EYEGUARD-B trial failed to meet its primary endpointand the medicine did not significantly alter the risk of flares.[72]. This evidence concerns the gene IL1B and uveitis.